Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Accord Healthcare Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (614)
Cancellation by sponsor (126)
Prescription medicine registration (46)
Australian Public Assessment Report (AusPAR) (3)

Date

2026 (59)
2025 (69)
2024 (32)
2023 (69)
2022 (85)
2021 (52)
2020 (48)
2019 (93)
2018 (64)
2017 (40)
2016 (70)
2015 (36)
2014 (33)
2013 (7)
2012 (16)
2011 (16)

Search

Sponsor content

789 result(s) found, displaying 681 to 690

DOCETAXEL INTAS 160 mg/8 mL docetaxel concentrated injection 160 mg/8 mL glass vial (209468)

17 February 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DOCETAXEL INTAS 160 mg/8 mL docetaxel concentrated injection 160 mg/8 mL glass vial.
FLUOROURACIL ACCORD, FLUOROURACIL INTAS (Accord Healthcare Pty Ltd)

5 June 2018

Prescription medicine registration

Active ingredients: Fluorouracil.
ACCORD DOXORUBICIN doxorubicin hydrochloride 200 mg/100 mL concentrated solution for injection vial Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
ACCORD DOXORUBICIN doxorubicin hydrochloride 10 mg/5 mL concentrated solution for injection vial Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDAZOLAM WP Midazolam (as hydrochloride) 5 mg/1 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDALIM Midazolam (as hydrochloride) 5 mg/1 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDALIM Midazolam (as hydrochloride) 5 mg/5 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDAVEL Midazolam (as hydrochloride) 50 mg/10 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDAZOLAM WP Midazolam (as hydrochloride) 5 mg/5 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd
MIDAVEL Midazolam (as hydrochloride) 15 mg/3 mL solution for injection ampoules Cancelled under Section 30(1)(c) of the Act

7 May 2018

Cancellation by sponsor

Requested by Accord Healthcare Pty Ltd

Pages

First page
Previous page
…
Page 65
Page 66
Page 67
Page 68
Current page 69
Page 70
Page 71
Page 72
Page 73
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.